Table 1.
Demographic information and first-cycle IVF protocols for fertility preservation patients and matched controls.
| Cases (n = 50) | Controls (n = 50) | |
|---|---|---|
| Age (years) | 31.2 (19–13) | 31.2 (21–41) |
| Body mass index (kg/m2) | 24.2 (19–47) | 24.4 (18–44) |
| Race (Caucasian) | 88 (44/50) | 88 (44/50) |
| Previous pregnancy | 32 (16/50) | 48 (24/50) |
| Previous pregnancya | 1 (1–5) | 2 (1–8) |
| Cancer type | ||
| Breast | 58 (29/50) | – |
| Hodgkin's lymphoma | 4 (2/50) | – |
| Myelodysplastic syndrome | 6 (3/50) | – |
| Ovarian cancer | 6 (3/50) | – |
| Cervical cancer | 6 (3/50) | – |
| Endometrial cancer | 4 (2/50) | – |
| Other cancer | 6 (3/50) | – |
| Non-malignancy | 10 (5/50) | – |
| First-cycle protocolb | ||
| Letrozole | 44 (22/50) | 0 (0/50) |
| Antagonist without letrozole | 44 (22/50) | 40 (20/50) |
| Luteal-phase lupron | 12 (6/50) | 60 (30/50) |
| Trigger medication | ||
| HCG | 78 (39/50) | 86 (43/50) |
| GnRH | 16 (8/50) | 14 (7/50) |
| Both | 6 (3/50) | 0 (0/50) |
Values are median (range) or % (n).
a
For those with previous pregnancy.
b
P< 0.001.
GnRH = gonadotrophin-releasing hormone; HCG = human chorionic gonadotrophin.